{'fraction_non_alphanumeric': 0.05186020293122886, 'fraction_numerical': 0.04171364148816235, 'mean_word_length': 4.842105263157895, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression of multidrug-resistance (MDR1) gene in normal epithelia and in invasive carcinomas of the uterine cervix.

Total RNA from 92 invasive cervical cancers was analyzed for the presence of multidrug-resistance (MDR1) gene (also known as PGY1) transcripts. A 4.5-kilobase MDR1 transcript band was detected in 40 (43%) of 92 invasive cervical carcinomas and in 15 (68%) of 22 normal cervices. MDR1 levels were low [mean, 2.5 arbitrary units (U)] except in one liver metastasis (50 U) treated with a drug regimen including vincristine. Of eight carcinomas treated by radiotherapy and/or chemotherapy, seven (88%) exhibited MDR1 transcripts as compared with 24 (35%) of 69 untreated carcinomas (Fisher's exact test; P = .01). In conclusion, our data suggest that the MDR1 gene plays a role in drug resistance of certain cervical cancers, but also that other mechanisms may be involved.